



*vaccines*



an Open Access Journal by MDPI

## SARS-CoV-2 Variants Research and Ending the COVID-19 Pandemic

Guest Editors:

**Dr. Claudia Maria Trombetta**

Department of Molecular and Developmental Medicine,  
University of Siena, Banchi di Sotto, 55, 53100 Siena, SI, Italy

**Prof. Emanuele Montomoli**

Department of Molecular and Developmental Medicine,  
Università degli Studi di Siena, Siena, Italy

**Dr. Serena Marchi**

Department of Molecular and Developmental Medicine,  
University of Siena, 53100 Siena, Italy

### Message from the Guest Editors

Since the end of January 2020, the world has been experiencing a disastrous pandemic caused by a novel coronavirus, named SARS-CoV-2, first identified in Wuhan, China, and which rapidly spread worldwide. The pandemic has devastated healthcare systems, imposed strict national lockdown, and is responsible for over a million deaths across the world.

The emergence of new and more infectious SARS-CoV-2 variants is raising concern, and vaccination may represent a primary tool to counteract the pandemic, virus spread, and mortality.

In this Special Issue, we aim to cover all aspects related to SARS-CoV-2 variants, vaccines, and immune response. The goal is to provide an overview of the most relevant investigations related to SARS-CoV-2 and the COVID-19 pandemic.

Deadline for manuscript submissions:

**closed (31 December 2022)**



[mdpi.com/si/92644](https://mdpi.com/si/92644)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)